Misplaced Pages

Thymectacin: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editContent deleted Content addedVisualWikitext
Revision as of 01:36, 24 January 2023 editEntranced98 (talk | contribs)Extended confirmed users, Pending changes reviewers, Rollbackers172,963 edits Importing Wikidata short description: "Chemical compound"Tag: Shortdesc helper← Previous edit Latest revision as of 14:07, 12 August 2023 edit undoOAbot (talk | contribs)Bots441,761 editsm Open access bot: doi added to citation with #oabot. 
Line 42: Line 42:
}} }}


'''Thymectacin''' ('''NB-1011''', '''NB-101''') is an experimental anticancer ] of ] monophosphate. It is being ] by ] and it entered in phase I clinical trials for colon cancer in 2006.<ref>{{cite journal | vauthors = Wilson RH | title = Novel therapeutic developments other than EGFR and VEGF inhibition in colorectal cancer | journal = The Oncologist | volume = 11 | issue = 9 | pages = 1018–24 | date = October 2006 | pmid = 17030644 | doi = 10.1634/theoncologist.11-9-1018 | url = http://theoncologist.alphamedpress.org/cgi/content/full/11/9/1018 }}</ref> '''Thymectacin''' ('''NB-1011''', '''NB-101''') is an experimental anticancer ] of ] monophosphate. It is being ] by ] and it entered in phase I clinical trials for colon cancer in 2006.<ref>{{cite journal | vauthors = Wilson RH | title = Novel therapeutic developments other than EGFR and VEGF inhibition in colorectal cancer | journal = The Oncologist | volume = 11 | issue = 9 | pages = 1018–24 | date = October 2006 | pmid = 17030644 | doi = 10.1634/theoncologist.11-9-1018 | url = http://theoncologist.alphamedpress.org/cgi/content/full/11/9/1018 | doi-access = free }}</ref>


Thymectacin is a small molecule phosphoramidate derivative of (''E'')-5-(2-bromovinyl)-2'-deoxyuridine (BVdU) with potential antineoplastic activity.<ref>{{cite web | url = https://www.cancer.gov/publications/dictionaries/cancer-drug/def/brivudine-phosphoramidate | title = Brivudine phosphoramidate | work = NCI Drug Dictionary | publisher = ] }}</ref> It is selectively active against tumor cells expressing high levels of ] (TS). Thymectacin is converted intracellularly by TS to bromovinyldeoxyuridine monophosphate (BVdUMP) which competes with the natural substrate, ], for binding to TS. Unlike TS inhibitors, this agent is a reversible substrate for TS catalysis. Thus, TS retains activity and converts BVdUMP into cytotoxic metabolites. Thymectacin is a small molecule phosphoramidate derivative of (''E'')-5-(2-bromovinyl)-2'-deoxyuridine (BVdU) with potential antineoplastic activity.<ref>{{cite web | url = https://www.cancer.gov/publications/dictionaries/cancer-drug/def/brivudine-phosphoramidate | title = Brivudine phosphoramidate | work = NCI Drug Dictionary | publisher = ] }}</ref> It is selectively active against tumor cells expressing high levels of ] (TS). Thymectacin is converted intracellularly by TS to bromovinyldeoxyuridine monophosphate (BVdUMP) which competes with the natural substrate, ], for binding to TS. Unlike TS inhibitors, this agent is a reversible substrate for TS catalysis. Thus, TS retains activity and converts BVdUMP into cytotoxic metabolites.

Latest revision as of 14:07, 12 August 2023

Chemical compound Pharmaceutical compound
Thymectacin
Skeletal formula of thymectacin
Space-filling model of the thymectacin molecule
Clinical data
Other namesNB-1011; NB-101; N--2'-deoxyuridin-5'-O-yl]](phenoxy)phosphoryl]-L-alanine methyl ester
Identifiers
IUPAC name
  • (2S)-methyl 2-((((2R,3S,5R)-5-(5-((E)-2-bromovinyl)-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC21H25BrN3O9P
Molar mass574.321 g·mol
3D model (JSmol)
SMILES
  • C(C(=O)OC)NP(=O)(OC1(C(O1)n2cc(c(=O)c2=O)/C=C/Br)O)Oc3ccccc3
InChI
  • InChI=1S/C21H25BrN3O9P/c1-13(20(28)31-2)24-35(30,34-15-6-4-3-5-7-15)32-12-17-16(26)10-18(33-17)25-11-14(8-9-22)19(27)23-21(25)29/h3-9,11,13,16-18,26H,10,12H2,1-2H3,(H,24,30)(H,23,27,29)/b9-8+/t13-,16-,17+,18+,35?/m0/s1
  • Key:CFBLUORPOFELCE-BACVZHSASA-N
  (what is this?)  (verify)

Thymectacin (NB-1011, NB-101) is an experimental anticancer prodrug of brivudine monophosphate. It is being developed by New Biotics and it entered in phase I clinical trials for colon cancer in 2006.

Thymectacin is a small molecule phosphoramidate derivative of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVdU) with potential antineoplastic activity. It is selectively active against tumor cells expressing high levels of thymidylate synthase (TS). Thymectacin is converted intracellularly by TS to bromovinyldeoxyuridine monophosphate (BVdUMP) which competes with the natural substrate, deoxyuridine monophosphate, for binding to TS. Unlike TS inhibitors, this agent is a reversible substrate for TS catalysis. Thus, TS retains activity and converts BVdUMP into cytotoxic metabolites.

References

  1. Wilson RH (October 2006). "Novel therapeutic developments other than EGFR and VEGF inhibition in colorectal cancer". The Oncologist. 11 (9): 1018–24. doi:10.1634/theoncologist.11-9-1018. PMID 17030644.
  2. "Brivudine phosphoramidate". NCI Drug Dictionary. National Institutes of Health.
Stub icon

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

Categories: